Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort

Archive ouverte : Article de revue

Faiz, Sarah | Giovannelli, Jonathan | Podevin, Céline | Jachiet, Marie | Bouaziz, Jean-David | Reguiai, Ziad | Nosbaum, Audrey | Lasek, Audrey | Ferrier Le Bouedec, Marie-Christine | Du Thanh, Aurélie | Raison-Peyron, Nadia | Tetart, Florence | Duval-Modeste, Anne-Benedicte | Misery, Laurent | Aubin, François | Dompmartin, Anne | Morice, Cécile | Droitcourt, Catherine | Soria, Angele | Arnault, Jean-Philippe | Delaunay, Juliette | Mahé, Emmanuel | Richard, Marie-Aleth | Schoeffler, Amélie | Lacour, Jean-Philippe | Begon, Edouard | Walter-Lepage, Amélie | Dillies, Anne-Sophie | Rappelle-Duruy, Sandrine | Barete, Stéphane | Bellon, Nathalia | Beneton, Nathalie | Valois, Aude | Barbarot, Sébastien | Sénéchal, Julien | Staumont-Sallé, Delphine

Edité par HAL CCSD ; Elsevier

International audience. BackgroundDupilumab is the first biologic available to treat atopic dermatitis (AD). Its effectiveness and safety were demonstrated in clinical trials.ObjectiveWe sought to assess the effectiveness and safety of dupilumab in adults with AD in a real-life French multicenter retrospective cohort.MethodsWe included patients treated during March 2017-April 2018. Efficacy outcomes, including Scoring Atopic Dermatitis (SCORAD) and Eczema Area and Severity Index (EASI) scores, were collected at baseline and 3 months when available. Adverse events (AEs) were recorded at follow-up.ResultsWe included 241 patients. The median ± interquartile range (IQR) follow-up time was 3.8 ± 3.7 months. A ≥75% improvement in SCORAD was achieved in 27 of 163 (16.6%) patients, and a ≥75% improvement in EASI was achieved in 40 of 82 (48.8%) patients. The median SCORAD and EASI scores at 3 months were significantly lower than those at baseline (SCORAD ± IQR, 25 ± 21 vs 56 ± 27.4, P < 10−9 and EASI ± IQR, 4.1 ± 6.8 vs 17.9 ± 15.4, P < 10−9, respectively). Conjunctivitis was reported in 84 of 241 (38.2%) patients. The proportion with eosinophilia (>500 cells/mm3) during follow-up (57%) was higher than that at baseline (33.7%) (n = 172, P < 10−6). Dupilumab was stopped in 42 cases; 27 patients stopped because of AEs.LimitationsNo control group, missing data.ConclusionThis real-life study demonstrated a similar dupilumab effectiveness as that seen in clinical trials, but it also revealed a higher frequency of conjunctivitis and eosinophilia.

Consulter en ligne

Suggestions

Du même auteur

Effectiveness and tolerance of Janus kinase inhibitors for the treatment of recalcitrant atopic dermatitis in a real-life French multicenter adult cohort | Vanlerberghe, Julia

Effectiveness and tolerance of Janus kinase inhibitors for the treatment of...

Archive ouverte: Article de revue

Vanlerberghe, Julia | 2022

International audience

Efficacité et tolérance du dupilumab dans le traitement de la dermatite atopique de l’enfant de moins de 12 ans en vie courante : cohorte rétrospective multicentrique française | Lasek, Audrey

Efficacité et tolérance du dupilumab dans le traitement de la dermatite ato...

Archive ouverte: Article de revue

Lasek, Audrey | 2021-12

International audience

Evaluation of children with Psoriasis from the BiPe Cohort: are patients using biotherapies in real life eligible for phase III clinical studies? | Phan, Céline

Evaluation of children with Psoriasis from the BiPe Cohort: are patients us...

Archive ouverte: Article de revue

Phan, Céline | 2019

International audience. Background Phase III clinical trials of biotherapies for childhood psoriasis are designed for a selected population, which can differ from real-life patients. Objective Our objective was to a...

Du même sujet

Proteolytic activity of Lactobacillus strains isolated from Mongolian traditional dairy products: A multiparametric analysis | Raveschot, Cyril

Proteolytic activity of Lactobacillus strains isolated from Mongolian tradi...

Archive ouverte: Article de revue

Raveschot, Cyril | 2020-01-30

Le Réseau Mixte Technologique Sols et Territoires : développer la connaissance des sols dans les territoires. Le Réseau Mixte Technologique Sols et Territoires : développer la connaissance des sols dans les territoires: Principes, bilan et perspectives | Guellier, Camille

Le Réseau Mixte Technologique Sols et Territoires : développer la connaissa...

Archive ouverte: Article de revue

Guellier, Camille | 2014

absent

Soil bioindicators: how soil properties influence their responses and to select them in function of the site issues? | Pauget, Benjamin

Soil bioindicators: how soil properties influence their responses and to se...

Archive ouverte: Communication dans un congrès

Pauget, Benjamin | 2015-05-03

International audience

Les incitations financières à la réalisation d’objectifs comportementaux liés à la santé. Les incitations financières à la réalisation d’objectifs comportementaux liés à la santé: État des lieux et questions en suspens | Crainich, David

Les incitations financières à la réalisation d’objectifs comportementaux li...

Archive ouverte: Article de revue

Crainich, David | 2022-02

International audience. Les programmes octroyant des récompenses pécuniaires aux individus qui parviennent à atteindre un objectif lié à la santé (arrêter de fumer, perdre du poids, etc.) ont pour but de favoriser l...

Transcriptome assembly and abiotic related gene expression analysis of date palm reveal candidate genes involved in response to cadmium stress | Rekik, Imen

Transcriptome assembly and abiotic related gene expression analysis of date...

Archive ouverte: Article de revue

Rekik, Imen | 2019-11-30

Characterization of free exopolysaccharides secreted by <em>Mycoplasma mycoides</em> subsp. <em>mycoides</em> | Bertin, Clothilde

Characterization of free exopolysaccharides secreted by Mycoplasma myco...

Archive ouverte: Article de revue

Bertin, Clothilde | 2013

International audience. Contagious bovine pleuropneumonia is a severe respiratory disease of cattle that is caused by a bacterium of the Mycoplasma genus, namely Mycoplasma mycoides subsp. mycoides (Mmm). In the abs...

Chargement des enrichissements...